[Drugs interfering with platelet function].

A Marino; G De Natale

Home/Archive/PubMed

PubMed · 2159394

[Drugs interfering with platelet function].

A Marino·G De Natale

View original source ↗Export metadata ↓

Abstract

Drugs interfering with platelet aggregation pathways and Ca2+ availability were reviewed. Particularly receptor antagonists, drugs affecting intracellular concentration of cAMP and drugs acting on enzymes involved in the synthesis of PGE2 and PGF2, thromboxane and PGI, were considered.

Explore related subjects

Blood Coagulation Factors Blood Platelets Calcium Cyclic AMP Platelet Activating Factor Platelet Aggregation Platelet Aggregation Inhibitors Prostaglandins Receptors, Cell Surface English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

A Marino, G De Natale. 1990-02-15. [Drugs interfering with platelet function].. https://pubmed.ncbi.nlm.nih.gov/2159394/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Purification of factor X by hydrophobic interaction chromatography.

Human factor X has been purified to homogeneity by hydrophobic interaction chromatography on phenyl-sepharose. The coagulation protein did not interact with the resin in the presence of 2-3 M NaCl whereas contaminants were retained. This single purification step, in conjunction with classical purification strategies, is a powerful tool in generating high purity factor X and is based on resins which are readily available.

Blood Coagulation Factors↗

PubMed2001

[Blood is a special juice].

Explore the source record for details and available documents.

Blood Coagulation Factors↗

PubMed2001

[Gene polymorphisms of hemostasis and coronary risk].

Hemostatic disorders are substantially involved in the pathogenesis of coronary heart disease and acute coronary syndromes. In addition to biochemical markers, gene polymorphisms of hemostasis have been intensively studied in terms of their association with coronary risk. These include polymorphisms of the genes of platelet glycoproteins, fibrinogen, prothrombin, factors V, VIII and XIII, plasminogen activator inhibitor-1 and tissue-type plasminogen activator. An association of a certain gene polymorphism with an increased coronary risk has usually been demonstrated in retrospective case-control studies. However, numerous clinical studies have not yet been able to identify any of these polymorphisms as unequivocal risk factors of coronary heart disease or acute coronary syndromes. These inconsistencies are mainly due to the complexity of the pathogenesis of coronary heart disease and the minor contribution of a single polymorphism to total coronary risk. This review reports on essential requirements of future studies as a prerequisite to improve our understanding of the genetic basis of coronary heart disease.

Blood Coagulation Factors↗